Seer JPM Healthcare Conference Day 1: Seer, Twist, 10x, Guardant, Natera, Bruker, Adaptive, Qiagen, Sema4 Highlights of the first day included updates on Seer's new proteomics platform and a new enzymatic DNA synthesis chemistry from Twist Bioscience. Seer Collaborators Release Data Indicating Proteograph Platform's Utility for Proteomics Research Premium The company and its early-access users have recently published data from several studies indicating that its platform can boost plasma proteome coverage. Seer Q3 Revenues Spike but Firm Misses Wall Street Estimate on Earnings The proteomics firm posted revenues of $2.2 million, up from $72,000 in the year-ago period and above the consensus Wall Street estimate of $1.2 million. Seer Q2 Revenues Skyrocket; Firm Inks Chinese Distribution Deal The company posted revenues of $1.3 million, up from $71,000 in the year-ago period and above the consensus Wall Street estimate of $790,000. Seer Q1 Revenues Fall on Decline in Grant Revenue The Redwood City, California-based proteomics firm posted revenues of $62,000, down from $177,000 in the year-ago period due a decline in grant revenue. Jan 28, 2021 Seer Prices $110.5M Follow-on Stock Offering Jan 26, 2021 Seer Plans Offering of 3.5M Shares of Common Stock Breaking News NIH Earmarks $170M for All of Us Program's Personalized Nutrition Study Taiwanese Firm's IP Asserted in Suit Against Pacific Biosciences Found Partially Unpatentable In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health Centogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine Dilated Cardiomyopathy Gene Mutations Point to Possible Therapeutic Strategy Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm The Scan Transplant Tests Edited Pig Kidneys The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient. UK Changes Some Gene-Edited Crop Rules A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says. Pill Works Against Omicron in Lab Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports. Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.